Tennessee residents are exposed to a multitude of potential hazards posed by dangerous or defective products on a daily basis. It could be tainted food, dangerous chemicals in household cleaners or defective equipment, among others. However, consumers are exceptionally vulnerable when they are treated with defective medical products or dangerous drugs that could lead to severe — and even life-threatening — conditions and unanticipated medical expenses.
The branch of Teva that manufactures intravenous and intramuscular injections recently announced the voluntary recall of Adrucil. The company reported that it identified eight lots of Adrucil containing particulate matter. The foreign matter was determined to be a combination of fluorouracil crystals and pieces of rubber originating from a filler diaphragm.
The tainted vials were distributed to clients across the country and could cause life-threatening conditions in patients to whom it was administered. Adrucil is used in the treatment of patients with carcinoma of the stomach, breast, pancreas, rectum or colon. Carcinoma is a cancer that begins in tissues that cover or line body organs. If these tainted products are administered, it may lead to allergic reactions and inflammation or the blockage of blood vessels that may result in organ tissue damage. In severe cases, it could cause death.
Drug companies typically invest millions of dollars in research and development of new and better medication, but then sadly fail to monitor the manufacturing process to avoid the distribution of defective medical products or dangerous drugs. Tennessee residents who have suffered adverse consequences after being treated with tainted medication may pursue compensation for any unanticipated medical expenses and other monetary losses. Proper documentation to substantiate a product liability claim in a civil court, along with a successful presentation, may result in financial relief being awarded.
Source: pharmacytimes.com, “Teva Recalls Adrucil Injections Distributed to Pharmacies“, Krystle Vermes, May 6, 2015